Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-labeled vartumabs (F8scFv and C9scFv) PET/CT imaging in solid tumors
NCT06645808Phase 1Recruiting
- Sponsor
- VAR2 Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label trial of 89Zr-F8scFv and vartumab (2 arms), sponsored by VAR2 Pharmaceuticals. Primary endpoints: Biodistribution and pharmacokinetics of the radiolabeled IMP at 4 days, Tumor-specific uptake of the IMP at 7 days and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
89Zr-F8scFvvartumab
Beyond the preview
Go deeper on NCT06645808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645808.